Delivery of highly cytotoxic reagents by an antibody construct at the tumor site has been an attractive concept for quite some time and was supported by the availability of first-generation CD30-specific antibodies with favorable tumor-targeting properties in cHL patients. The gene discussed is TNFRSF8; the disease is classic Hodgkin lymphoma.